Zacarķas FM

Language: Spanish
References: 11
Page: 83-84
PDF size: 61.94 Kb.

Text Extraction

No abstract

REFERENCES

1. National Institute of Allergy and Infectious Diseases. Human papillomavirus and genital warts. Available from: URL: http://www.niaid.nih.gov/factsheets/stdhpv.htm. August 2006.

2. Kjaer SK, van den Brule AJC, Bock JE, Poll PA, Engholm G, Sherman ME, et al. Human papillomavirus -the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996; 65: 601-606.

3. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. Lyons, France: IARC Press; 2001.

4. de Villiers EM. Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001; 12: 57-63.

5. Centers for Disease Control and Prevention National Immunization Program. Record of the meeting of the advisory Committee on Immunization Practices. February 21-22, 2006. Available from: URL: http://www.cdc.gov/nip/ACIP/minutes/acip_min_feb06.pdf

6. Harro CD, Pang Y-YS, Roden RBS, Hildesheim A, Wang Z, Reynolds JM, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-292.

7. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.

8. Schiffman M, Castle PE. Epidemiology of HPV. Arch Pathol Lab Med 2003; 127: 930-934.

9. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 (Suppl 1): S7-S15.

10. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32: S16-S24.

11. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.